Clicky

Bioventix Plc(BVXP)

Description: Bioventix PLC is a United Kingdom-based biotechnology company. The principal activity of the Company is the development and supply of antibodies. The Company specializes in the development of sheep monoclonal antibodies (SMAs) for use in immunodiagnostics focusing on the areas of clinical diagnostics and drugs of abuse testing. The Company's non-vitamin D business consists of antibodies, NT proBNP (heart failure), testosterone, Free Triiodothyronine (FT3) (thyroid hormone), estradiol, and various drugs, such as tetrahydrocannabinol (THC)/cannabis, and progesterone. The Company offers products for indications, such as thyroid, fertility, oncology, cardiac, vitamin D, drug of abuse, infectious disease and miscellaneous. Its sheep hybridoma technology produces cell lines that secrete SMAs. The Company offers a panel of SMAs to 25-OH D and has various 25-OH D2 and 25-OH D3 specific antibodies. It sells its products through direct sales and through distributors.


Keywords: Biotechnology Disease Drugs Organ Systems Immunology Clinic Immune System Antibodies Oncology Monoclonal Antibodies Antibody Radio Heart Failure Glycoproteins Thyroid Testing Offers Products Testosterone E Testing Sheep Infectious Monoclonal Hybridoma Technology Progesterone

Home Page: www.bioventix.com

BVXP Technical Analysis

27–28 Eastcastle Street
London, W1W 8DH
United Kingdom
Phone: 44 12 5272 8001


Officers

Name Title
Mr. Peter John Harrison MA CEO & Director
Mr. Bruce Edward Heath Hiscock CFO & Director

Exchange: LSE

Country: UK

Currency: Pence sterling (p)

Forward PE: 24.2131
Trailing PE: 28.7671
Price-to-Book MRQ: 16.2611
Price-to-Sales TTM: 16.4024
IPO Date:
Fiscal Year End: June
Full Time Employees: 12
Back to stocks